Shire Confirms Rejection of AbbVie Proposal
Shire reports that AbbVie offer undervalued company.
In a June 20 statement, Shire confirms that the board had rejected a May 30, 2014 “unsolicited and highly conditional proposal” from AbbVie regarding a possible cash and share offer for Shire. Reuters estimated the value of the offer at $46 billion (27 billion-pounds).
Shire reports that the offer undermined the value of the company and its prospects, and the board had concerns with execution risks associated with the proposed structure, as AbbVie would redomicile in the UK for tax purposes.
The May 30 proposal followed two earlier proposals, which were also rejected, Shire reports. At AbbVie's request, Shire met with AbbVie to discuss key aspects of the Proposal. Following the meeting, Shire's board decided unanimously to reject the proposal on the basis that it fundamentally undervalued the company and its prospects.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
